H-VVVGADGVGK-OH

Ref. 3D-PP48592

Informations sur le produit

• Nom: H-VVVGADGVGK-OH

Description

Peptide H-VVVGADGVGK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VVVGADGVGK-OH include the following: Homology Modeling Epitopes of Kirsten Rat Sarcoma (KRAS) G12D, G12V and G12R as Pancreatic Ductal Adenocarcinoma Vaccine Candidates Y Yeni , N Nining - Turkish Computational and Theoretical Chemistry, 2023 - dergipark.org.trhttps://dergipark.org.tr/en/pub/tcandtc/issue/72053/1140158 Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity RA Mariuzza , D Wu, BG Pierce - Frontiers in Immunology, 2023 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1303304 Identification of T-cell receptors targeting KRAS-mutated human tumors QJ Wang, Z Yu, K Griffith, K Hanada, NP Restifo - Cancer immunology , 2016 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/4/3/204/468486 Mutated RAS: targeting the"Untargetable" with T cells PD Chatani, JC Yang - Clinical Cancer Research, 2020 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/26/3/537/83143 Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy N Levin , BC Paria, NR Vale, R Yossef , FJ Lowery - Clinical Cancer , 2021 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/27/18/5084/671639 Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations GP Linette, AS Bear , BM Carreno - Clinical Cancer Research, 2024 - AACRhttps://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-1212/733759 Identification of neoepitope reactive T-cell receptors guided by HLA-A* 03: 01 and HLA-A* 11: 01 immunopeptidomics CM Ade, MJ Sporn, S Das , Z Yu, K Hanada - for Immunotherapy of , 2023 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537849/ Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen A Poole, V Karuppiah , A Hartt, JN Haidar - Nature , 2022 - nature.comhttps://www.nature.com/articles/s41467-022-32811-1

• Marque: Biosynth